U.S. Food and Drug Administration approved the first liquid biopsy companion diagnostic for sarcoma biopsy market

 

Sarcoma Biopsy Market

The growing prevalence of osteosarcoma is expanding the size of the global sarcoma biopsy market. Osteosarcoma is the most common type of cancer affecting bones. According to the American Cancer Society, IN January 2020, around 800 to 900 new cases of osteosarcoma are diagnosed in the U.S. each year, with around 50% occurs in children and teenagers. Also, the advent of an advanced diagnostic test for diagnosing cancer is again expected to foster the growth of the sarcoma biopsy market. Needle biopsy and surgical biopsy are the fastest-growing segments in the sarcoma biopsy market.

North America is expected to hold a dominant position in the global sarcoma biopsy market due to increasing healthcare expenditure in the U.S. For instance, according to the Committee for a Responsible Federal Budget, in 2017, the U.S. spent around the US $ 3.5 trillion, or 18% of the total GDP, on health expenditures, which is more than twice the average among developed countries.

In January 2020, the U.S. Food and Drug Administration approved Tazverik (tazemetostat) for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma

In August 2020, U.S. Food and Drug Administration approved the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology to identify patients with specific types of mutations of the epidermal growth factor receptor (EGFR) gene in a deadly form of metastatic non-small cell lung cancer (NSCLC)

In April 2021, Genetron Holdings Limited a precision oncology platform company in China that specializes in molecular profiling tests, early cancer screening products, and companion diagnostics development, announced the release of 22 research results at the American Association for Cancer Research Annual Meeting 2021 (AACR 2021)

Sarcoma can be one of the most fatal forms of cancer, and as such, there is an increased interest in Sarcoma Biopsies amongst both the public and healthcare professionals. It is therefore of great importance that Sarcoma Biopsies is obtained from an experienced and reliable source. With this in mind, it would be safe to say that the medical sarcoma biopsy industry would see phenomenal growth in terms of both patients and revenue. Sarcoma Biopsies is highly flexible in terms of the patients it can accommodate and their respective requirements. Not only can a patient choose to undergo a sarcoma biopsy either alone or in conjunction with another form of surgical procedure, but they can also choose to undergo a full-body surgical procedure as well as receive a non-surgical procedure


Comments

Popular posts from this blog

Fitness Equipment Market is doing warm-ups to pull growth-rich opportunities from the growing obesity rates accompanied by the sedentary lifestyles

The market for ureteral stents would benefit from the rising prevalence of urological diseases

Increased Prevalence of Chronic Diseases and Stem Cell Therapy R&D to Drive Stem Cell Assay Market Growth